Sucampo announces positive results from Phase Ia mucositis and stenosis trials
Aug 16, 2013 (MarketLine via COMTEX) --
Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, has announced positive results of two recently completed clinical trials, a Phase Ia trial of cobiprostone and a Phase Ia trial of SPI-3608. Cobiprostone is indicated for treatment of oral mucositis and SPI-3608 is indicated for treatment of mild to moderate lumbar spinal stenosis.
The studies tested the tolerability and pharmacokinetic profiles versus placebo of the two compounds, both of which were demonstrated to be generally well-tolerated in the tested populations.
The Phase Ia clinical trial for the investigational oral spray formulation of cobiprostone demonstrated that the drug is generally well-tolerated in healthy volunteers.
"Oral mucositis is an extremely painful and often debilitating side effect of radiation therapy and chemotherapy in cancer patients, with limited prescription treatments available," said Ryuji Ueno, M.D., Ph.D., Ph.D., Chairman, CEO, and Chief Scientific Officer of Sucampo. "In oral mucositis, with the breakdown of the mucosal barrier function, ulcers form as surface cells die. Our preclinical data indicate that cobiprostone induces mucosal barrier repair and prevents mucosal barrier damage, and the fact that it was well-tolerated in this study is extremely encouraging. Even though we have not yet evaluated efficacy in patients, we are looking forward to advancing cobiprostone into Phase Ib later this year."
The single-center, randomized, double-blind, placebo-controlled, dose-escalation study conducted in Japan was designed to assess tolerability and pharmacokinetics of a single dose of cobiprostone oral spray versus placebo in healthy adults aged 21-50 years. Approximately 48 individual subjects were analyzed, 36 of whom were treated with cobiprostone.
The study consisted of six escalating-dose steps and one repeat-dose step. In total, six doses of cobiprostone were tested. No serious or severe adverse events (AEs) were reported and the most frequently observed AE was mild diarrhea.
Sucampo also announced the positive top-line results of SPI-3608 in a Phase Ia single-oral-dose study that demonstrated the drug to be generally well tolerated in healthy volunteers. SPI-3608 is being investigated for the treatment of mild to moderate lumbar spinal stenosis (LSS) and may be investigated for additional indications in the future.
"Spinal stenosis is a common degenerative disease, caused by the narrowing of and diminished blood flow to the spinal cord. There are an estimated 400,000 Americans suffering from the pain associated with this disease, which can include numbness and muscle weakness in the lower extremities," said Dr Ueno. "Our preclinical data on SPI-3608 indicate that the compound is capable of the treatment of spinal stenosis by increasing spinal cord blood flow. This is an underserved market because there are currently limited options to treat lumbar spinal stenosis, and we are excited to continue investigating SPI-3608 to address this unmet need."
The clinical pharmacology study conducted in Japan assessed the tolerability and pharmacokinetics of SPI-3608 after a single oral administration in healthy men aged 20 to 37 years. Approximately 48 individuals were analyzed in this single-center, randomized, placebo-controlled, double-blind, dose-escalation study, 36 of which were treated with SPI-3608. In total, six doses of SPI-3608 were tested.
No serious or severe AEs were observed and the most frequently observed AE was mild vomiting. These findings showed that SPI-3608 is generally well-tolerated at all doses tested in the study.
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall
not be liable for errors or delays in the content, or for any actions
taken in reliance thereon
[ Back To Technology News's Homepage ]